Price
$96.55+16.47%Social Signal Score
Analyst Ratings
42 analystsRevenue
$2.06B+2.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ivan Tornos
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 17,000
- Beta
- 0.47
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.39
Financials
Revenue
$2.06B+2.5%Net Income
$191.60M+175.3%EBITDA
$587.10M+57.4%Free Cash Flow
$372.50M-34.9%EPS (diluted)
$1.00+212.1%Shares Outstanding (diluted)
191.40M-8.2%Operating Expenses
$960.90MCash & Debt
$399.90MReturn of Capital
$124.30MRevenue by Segment (annual)
$7.57BDividend per Share
$0.24Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.23B | $705.20M | $3.56 |
| 2024 | $7.68B | $903.80M | $4.45 |
| 2023 | $7.39B | $1.02B | $4.91 |
| 2022 | $6.94B | $231.40M | $1.10 |
| 2021 | $6.83B | $401.60M | $1.87 |
| 2020 | $6.13B | $-138.90M | $-0.65 |
| 2019 | $7.98B | $1.13B | $5.36 |
| 2018 | $7.93B | $-379.20M | $-1.81 |
| 2017 | $7.80B | $1.81B | $8.84 |
| 2016 | $7.67B | $305.90M | $1.47 |
| 2015 | $6.00B | $147.00M | $0.26 |
| 2014 | $4.67B | $720.30M | $4.14 |
| 2013 | $4.62B | $761.00M | $4.36 |
| 2012 | $4.47B | $755.00M | $4.19 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ZBH's reported EPS growth of -1.3% a year over 13 years.
- EPS in 5 years
- $3.34
- Implied price
- $83.40
- Return from $101.10
- -3.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $41.47 — -59.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -11.3% | -19.9% | -16.5% | -13.5% | -10.9% | -8.6% |
| -6.3% | -15.4% | -11.8% | -8.7% | -5.9% | -3.4% |
| -1.3% | -10.9% | -7.1% | -3.8% | -0.9% | 1.7% |
| 3.7% | -6.4% | -2.4% | 1.1% | 4.1% | 6.9% |
| 8.7% | -1.9% | 2.3% | 6.0% | 9.2% | 12.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-33.33%Social Signal Score
Mentions (28)
- News (RSS)seekingalpha·19h ago·Neutral
Zimmer Biomet: Fixing Its Own House While Its Rivals Are Distracted
View source ↗ - Newsseekingalpha.com·1d ago·Positive
…ed Zimmer Biomet remains a bullish opportunity: its transformation is nearing completion as major competitors face disruption, opening a potential share-gain window. ZBH trades at 9.66x forward EV/EBITDA despite nearly 80% free cash flow conversion and approximately $2 billion in expected annual operating cash flow. In 2027, easing China headwinds, ROSA Shoulder and a potential Monogram launch could support growth; knees now represent roughly one-third of ZBH's business.
View source ↗ - News (RSS)seekingalpha·1d ago·Positive
Zimmer Biomet: Solid Sales And Cash Flow Drive A Buy
View source ↗ - Newsdefenseworld.net·1d ago·Negative
45,839 Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Boston Partners Boston Partners lifted its position in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 6.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 755,041 shares of the medical equipment provider's stock after purchasing an additional 45,839 shares during the quarter.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Jefferies London Healthcare Conference Transcript Zimmer Biomet Holdings, Inc. (ZBH) Presents at Jefferies London Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·3d ago·Neutral
Zimmer Biomet Eyes Faster Growth in 2027, Targets Earlier Robotics Launch Zimmer Biomet NYSE: ZBH expects revenue growth to improve in 2027 after exceeding its own expectations in each of the first three quarters of 2026, CEO Ivan Tornos said during a Jefferies fireside chat.
View source ↗ - News (RSS)investing·5d ago·Neutral
Why is Zimmer Biomet stock climbing today?
View source ↗ - Newsmarketbeat.com·14d ago·Negative
What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call Zimmer Biomet NYSE: ZBH raised its 2026 sales growth and adjusted earnings outlook after third-quarter growth in hips, surgical specialties and technology offset continued weakness in its knee business.
View source ↗ - Newsprnewswire.com·16d ago·Negative
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery New Category Will Introduce a Closed-Loop Framework: Predict. Perform. Recover.
View source ↗ - Newszacks.com·17d ago·Positive
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsbenzinga.com·18d ago·Neutral
Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market Zimmer Biomet Holdings (NYSE:ZBH) stock is trading at a 52-week high after the better-than-expected third-quarter earnings.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2026 Earnings Call Transcript Zimmer Biomet Holdings, Inc. (ZBH) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Positive
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates Zimmer Biomet (ZBH) came out with quarterly earnings of $1.9 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.9 per share a year ago.
View source ↗ - Newsprnewswire.com·18d ago·Neutral
…t with the prior year period Company updates full-year 2026 financial guidance WARSAW, Ind., Nov. 4, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2026.
View source ↗ - News (RSS)zerohedge·18d ago·Neutral
Conservative Canadian MP Says His Father Was Offered Euthanasia Unprompted Conservative Canadian MP Says His Father Was Offered Euthanasia Unprompted Authored by Matthew Horwood via The Epoch Times,Conservative MP Bob Zimmer said his father was offered medical assistance in dying (MAID) toward the end of his life without asking for it, prompting the MP to question whether safeguards for the procedure are being followed.Zimmer said on X that his family was preparing to bring his father home from
View source ↗ - Newszacks.com·24d ago·Neutral
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards? ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.
View source ↗ - Newsprnewswire.com·24d ago·Negative
…rt surgeon judgment, reduce procedural burden and connect the episode of care WARSAW, Ind., Oct. 29, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its plans to host a featured symposium and booth discussions to reveal a new vision for intelligent orthopedic surgery at the 2026 Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS), taking place November 5–8 in the Dallas area.
View source ↗ - Newsprnewswire.com·40d ago·Neutral
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT Multi-Year Extension to Help Accelerate Adoption of Wireless, Handheld TMINI® System for Use with Zimmer Biomet's Persona® Knee System FREMONT, Calif. and WARSAW, Ind.
View source ↗ - Newsprnewswire.com·47d ago·Neutral
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results WARSAW, Ind., Oct. 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its third quarter earnings conference call will be webcast on Wednesday, November 4, 2026, at 8:30 a.m.
View source ↗ - Newsprnewswire.com·75d ago·Neutral
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and Data WARSAW, Ind.
View source ↗ - Newszacks.com·79d ago·Neutral
Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report? Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)seekingalpha·82d ago·Neutral
Zimmer Biomet: Showing Signs Of Life
View source ↗ - Newsseekingalpha.com·82d ago·Neutral
Zimmer Biomet - Showing Signs Of Life Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon.
View source ↗ - News (RSS)investing·86d ago·Neutral
Zimmer Biomet declares $0.24 quarterly dividend
View source ↗ - Newsprnewswire.com·86d ago·Neutral
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026 WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026.
View source ↗ - Newszacks.com·94d ago·Neutral
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now? ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
View source ↗ - Newszacks.com·104d ago·Positive
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsmarketbeat.com·105d ago·Negative
Zimmer Biomet Q2 Earnings Call Highlights Zimmer Biomet NYSE: ZBH reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines.
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $2.49 per share
Typical surprise +2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$1.90 vs $1.88beat
- Wed, Aug 5$2.07 vs $2.01beat
- Tue, Apr 28$2.09 vs $1.86beat
- Tue, Feb 10$2.42 vs $2.38beat
- Wed, Nov 5$1.90 vs $1.87beat
- Thu, Aug 7$2.07 vs $1.98beat
Estimates and results for ZBH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZBH officers and directors.
- Bought
- —
- Sold
- $1.5m
0 trades
5 trades
- Thornal Kevin Rsold
- Phipps Chad Fsold
- Yi Sangsold
- Yi Sangsold
- Winkler Lorisold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (25d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (25d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (20d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (37d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 8, 2025 (30d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 10, 2025 (30d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Mar 13, 2025 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 11, 2024 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2024 (26d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
